अApnaFunda
Menu

POLY MEDICURE LTD (POLYMED)

Health Technology · Medical Specialties · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.71 / 100
Profitability 56Growth 70Balance sheet 86
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.27 / 100
Price 42Earnings 20FII/DII 19
Compare withINVENTURUS KNOWLEDGE SOLUINDEGENEANONDITA MEDICARE

Share price

Closing priceAdjusted for splits and bonus issues.

₹1,614.3 latest close · −3.8% over the last 90 sessions

₹1,600₹1,800Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹1,600₹1,800Jul 3Sep 4Nov 9

₹1,614.3 month-end · −16.8% over 12 months

₹1,250₹1,500₹1,750₹2,000Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹1,250₹1,500₹1,750₹2,000Nov '25May '26Nov '26

₹1,614.3 month-end · +5.8% over 3 years

₹2,000₹3,000Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹2,000₹3,000Nov '23May '25Nov '26

₹1,614.3 month-end · +648.4% since Jan '19

₹0₹1,000₹2,000₹3,000Jan '19Aug '20Mar '22Sep '23Apr '25Nov '26 ₹0₹1,000₹2,000₹3,000Jan '19Dec '22Nov '26

52-week range ₹1182.00 to ₹2094.30 · 1-year volatility 42.6%

Was the rally earned?

-17%share price, 1 yearEarnings-driven

Mostly earnings.

  • Per-share earnings took off 12 points, while the multiple moved less (P/E 54.9x to 51.9x).
  • The share count barely moved.
Net profit growth: −11 pts. Points of the price return explained by net profit growing (or shrinking).−11 ptsNet profit growthP/E change: −5 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−5 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: −17%−17%Share priceNet profit growth: −11 pts. Points of the price return explained by net profit growing (or shrinking).−11ProfitP/E change: −5 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−5P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: −17%−17%Share price
Net profit growth-11 ptsNet profit fell about 12%, which lowers the price.
P/E change-5 ptsThe P/E fell from 54.9x to 51.9x, which lowers the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+6%share price, 3 yearsLower P/E held it back

Mostly yes, with a catch.

  • Per-share earnings added 52 points, but investors now pay less per rupee of profit (P/E 81.6x to 51.9x), which took 46 points back.
  • The share count rose 6%.
Net profit growth: +58 pts. Points of the price return explained by net profit growing (or shrinking).+58 ptsNet profit growthP/E change: −46 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−46 ptsP/E changeShare count change: −6 pts. Points of the price return explained by the share count changing. More shares count against the price.−6 ptsShare count changeShare price: +6%+6%Share priceNet profit growth: +58 pts. Points of the price return explained by net profit growing (or shrinking).+58ProfitP/E change: −46 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−46P/EShare count change: −6 pts. Points of the price return explained by the share count changing. More shares count against the price.−6SharesShare price: +6%+6%Share price
Net profit growth+58 ptsNet profit rose about 76%, which lifts the price.
P/E change-46 ptsThe P/E fell from 81.6x to 51.9x, which lowers the price.
Share count change-6 ptsShare count rose 6%, which lowers the price.
+56%share price, 5 yearsLower P/E held it back

Mostly yes, with a catch.

  • Per-share earnings added 99 points, but investors now pay less per rupee of profit (P/E 73.2x to 51.9x), which took 43 points back.
  • The share count rose 6%.
Net profit growth: +106 pts. Points of the price return explained by net profit growing (or shrinking).+106 ptsNet profit growthP/E change: −43 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−43 ptsP/E changeShare count change: −7 pts. Points of the price return explained by the share count changing. More shares count against the price.−7 ptsShare count changeShare price: +56%+56%Share priceNet profit growth: +106 pts. Points of the price return explained by net profit growing (or shrinking).+106ProfitP/E change: −43 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−43P/EShare count change: −7 pts. Points of the price return explained by the share count changing. More shares count against the price.−7SharesShare price: +56%+56%Share price
Net profit growth+106 ptsNet profit rose about 132%, which lifts the price.
P/E change-43 ptsThe P/E fell from 73.2x to 51.9x, which lowers the price.
Share count change-7 ptsShare count rose 6%, which lowers the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with INVENTURUS KNOWLEDGE SOLU

How rough has the ride been?

Maximum drawdown-61.9%not yet recovered
1-year volatility42.6%annualised
Beta vs sector index0.903-year daily, correlation 0.33
Volume spikes3last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−20%−40%−60%2020202120222023202420252026−60.7% 0%−20%−40%−60%2020202220242026−60.7%
Largest drawdowns

-61.9% (2024-11 peak to 2026-03 low, not yet recovered)

-41.1% (2021-05 peak to 2022-06 low, recovered 2023-06)

-38.0% (2020-02 peak to 2020-03 low, recovered 2020-07)

Most recent volume spikes

2026-09-02: 7.4x the 50-day median, price +1.6% that day

2026-08-11: 9.6x the 50-day median, price +5.2% that day

2026-08-10: 7.8x the 50-day median, price +4.6% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

51.9xP/E todayWithin its usual range
Against its own history37th percentile
CheapestMedian 58.6xDearest

Usual range 27.8x to 83.1x since 2019-01.

Against Health Technology51.9x vs 37.0x
This company
51.9x
Sector median
37.0x

40% above the Health Technology median.

16.7x45.2x73.8x102.3xJan '19Aug '20Mar '22Oct '23May '25Nov '2616.7x45.2x73.8x102.3xJan '19Sep '21May '24Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE40th▼ 26 pts vs a year ago
  • Op. margin72nd▼ 7 pts vs a year ago
  • Revenue growth68th▼ 7 pts vs a year ago
  • EPS growth28th▼ 43 pts vs a year ago
  • Debt/equity ↓66th▼ 6 pts vs a year ago
  • Cash cycle ↓12th▼ 11 pts vs a year ago
  • P/E ↓29th▲ 3 pts vs a year ago
  • 12M momentum19th▼ 11 pts vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~29%annual earnings growth implied by the priceAbove delivered growth

At normalised P/E (five-year average earnings) of 65.3x, a holder earning 12%/yr needs earnings to grow about 29.2%/yr for 10 years, then trade at 15x.

Delivered22.8%/yrEPS, last 10 fiscal years · 3-yr avg to 3-yr avg
Gap+6.4 ptsimplied minus delivered
Rank400thmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

0%21%42% Jan 2019Nov 2026 0%21%42% Jan 2019Nov 2026

Change the assumptions

Exit P/E / return11%12%13%
12x30.9%32.1%33.2%
15x28.1%29.2%30.4%
20x24.5%25.6%26.8%

Drag a slider to test other assumptions

Implied: 29.2%/yr

Looking back

  • Jan 2020Price implied 22%/yr; EPS has since grown 23%/yr (7.0 yrs)
  • Jan 2021Price implied 29%/yr; EPS has since grown 19%/yr (6.0 yrs)
  • Jan 2022Price implied 35%/yr; EPS has since grown 17%/yr (5.0 yrs)

Past comparisons cover only companies listed today (survivorship bias) and say nothing about future outcomes.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹1614.30
P/E
51.9x
ROCE
12.0%
Market Cap
₹16357 cr
Revenue (TTM)
₹1998 cr
P/S
8.2x
P/B
5.3x
ROE
10.1%
Operating Margin
24.0%
Debt / Equity
0.1x
Promoter Holding
62.4%
12M Momentum
-16.8%

52-week range

₹1182.00₹2094.30
47% of the way from its 52-week low to its high

Price risk

1Y volatility
42.6%
Beta vs sector
1-year daily
1.11

Balance sheet & cash

Interest cover
operating profit ÷ interest
21.1x
Cash from profit, 3Y
operating cash flow ÷ net profit
0.81x
Share count, 1Y
unchanged

Are profits backed by cash?

4 of 7checks within range1 beyond a threshold
Other income reliance26%Near threshold

Other income as a share of pre-tax profit (trailing twelve months): 26.1%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate25%Within range

Median quarterly effective tax rate over about 2.5 years: 25.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion0.81xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 0.81x (cash from operations ₹745 cr, net profit ₹918 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow0 of 5 yrsBeyond threshold

Fiscal years with positive free cash flow in the last 5: 0. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+27 daysNear threshold

Debtor days are above the median of the previous three fiscal years by 27 days (103 vs 76). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress6% of fixed assetsWithin range

Capital work-in-progress is 6% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+2 days / 2 yrsWithin range

Days payable changed by +2 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 3 years, DIIs added 10.9 pts; promoters added 9.2 pts; FIIs trimmed 8.9 pts.
  • The number of shareholders rose from 34,649 to 73,643 (+113%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change
Promoters53.2%62.4%+9.3 pts
FIIs14.5%5.6%-8.9 pts
DIIs5.2%16.1%+10.9 pts
Public and others27.2%15.9%-11.3 pts

Number of shareholders

73,643shareholders+113% since Sep '23
35k48k61k74k Sep '23Jun '24Mar '25Dec '25Jun '26
Sep '23: 34,649
Dec '23: 36,053
Mar '24: 36,712
Jun '24: 36,852
Sep '24: 38,352
Dec '24: 60,686
Mar '25: 65,583
Jun '25: 71,142
Sep '25: 64,400
Dec '25: 67,750
Mar '26: 73,414
Jun '26: 73,643
 35k48k61k74k Sep '23Sep '24Sep '25Jun '26
Sep '23: 34,649
Dec '23: 36,053
Mar '24: 36,712
Jun '24: 36,852
Sep '24: 38,352
Dec '24: 60,686
Mar '25: 65,583
Jun '25: 71,142
Sep '25: 64,400
Dec '25: 67,750
Mar '26: 73,414
Jun '26: 73,643

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−2.2%typical 12-month return vs the marketNot meaningfully different from the base rate
  • We found 50 past situations where a non-financial company looked like POLY MEDICURE LTD today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −21% to +25% vs the market, against −5% for all non-financial companies in the same months.
  • The gap against the base rate (+2.8%, 80% range −5.0% to +10.4%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

−100%−50%0%+50%+100%
SEAMECLTD · Sep 2022: −49.9% vs market
EIHOTEL · Feb 2020: −46.1% vs market
NATCOPHARM · Jun 2021: −42.5% vs market
KANSAINER · Jun 2023: −38.6% vs market
FLUOROCHEM · May 2023: −37.9% vs market
SYNGENE · Oct 2025: −34.5% vs market
OLECTRA · Jan 2025: −30.3% vs market
CONCOR · Jun 2024: −28.6% vs market
RAILTEL · Jun 2025: −28.3% vs market
PARKHOTELS · Jun 2025: −27.7% vs market
ATUL · Aug 2022: −26.9% vs market
TTKPRESTIG · Dec 2021: −21.6% vs market
BORORENEW · Dec 2021: −21.4% vs market
ROUTE · Feb 2023: −20.6% vs market
LATENTVIEW · Jun 2024: −19.6% vs market
BOROLTD · Sep 2025: −15.7% vs market
SUNDROP · Jan 2021: −13.6% vs market
MTARTECH · Jan 2023: −13.1% vs market
COCHINSHIP · Aug 2025: −12.8% vs market
JYOTHYLAB · Jan 2020: −11.9% vs market
ETHOSLTD · Jun 2025: −7.5% vs market
SONACOMS · Nov 2023: −6.9% vs market
MEDANTA · Jan 2025: −4.4% vs market
MIDHANI · May 2025: −2.9% vs market
ATGL · Aug 2025: −2.4% vs market
CERA · Nov 2021: −2.0% vs market
UNOMINDA · Dec 2022: +3.9% vs market
TEGA · May 2025: +4.7% vs market
ANURAS · Jul 2022: +6.7% vs market
THERMAX · Nov 2022: +8.2% vs market
OBEROIRLTY · Sep 2022: +8.4% vs market
LAOPALA · Sep 2022: +10.0% vs market
FORTIS · Sep 2022: +10.9% vs market
METROPOLIS · Oct 2025: +17.1% vs market
BIKAJI · Dec 2023: +21.4% vs market
CARBORUNIV · Aug 2022: +23.0% vs market
SIRCA · Jan 2022: +23.1% vs market
PARAS · Feb 2024: +26.1% vs market
KIOCL · Dec 2022: +27.0% vs market
PIIND · Jun 2022: +27.6% vs market
RATEGAIN · Oct 2025: +32.3% vs market
AFFLE · Sep 2024: +32.9% vs market
RADICO · Jul 2022: +34.4% vs market
ELGIEQUIP · Apr 2022: +35.8% vs market
MAXHEALTH · May 2024: +42.4% vs market
AETHER · May 2025: +44.1% vs market
THYROCARE · Feb 2025: +45.5% vs market
EMAMILTD · May 2020: +47.7% vs market
ACUTAAS · Jul 2024: +110.7% vs market
HINDCOPPER · Mar 2025: +111.1% vs market
Similar setups −2.2%All companies −5.0%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 2 beyond the range shown, drawn at the edge

Similar setups' median
−2.2%
All companies' median
−5.0%
Beat the market
48% vs 44%

50 past situations · 50 companies · 34 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
MAXHEALTH
Health Services		 May 2024 66x15% +37%−16% +42%
RADICO
Consumer Non-Durables		 Jul 2022 48x16% +4%−26% +34%
CONCOR
Transportation		 Jun 2024 50x14% +58%−11% −29%
EIHOTEL
Consumer Services		 Feb 2020 63x10% −29%−36% −46%
LATENTVIEW
Commercial Services		 Jun 2024 65x15% +43%−10% −20%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
OBEROIRLTY
Finance		 Sep 2022 32x12% −5%−15% +8%
THERMAX
Producer Manufacturing		 Nov 2022 78x12% +17%−21% +8%
HINDCOPPER
Non-Energy Minerals		 Mar 2025 53x18% −21%−45% +111%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: 12-month momentum, drawdown from 12-month high and P/E. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to POLY MEDICURE LTD. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

YATHARTH HOSPITAL TRAUMAYATHARTH
Health Services
77%similar
operating marginP/E
AETHER INDUSTRIESAETHER
Process Industries
67%similar
ROCEvolatility
ANANT RAJANANTRAJ
Consumer Durables
65%similar
ROCEmarket cap
BOROSILBOROLTD
Producer Manufacturing
64%similar
P/EROCE
SAREGAMA INDIASAREGAMA
Consumer Services
63%similar
P/Epromoter holding
SHILPA MEDICARESHILPAMED
Health Technology
58%similar
volatilitymarket cap
GLAND PHARMAGLAND
Health Technology
57%similar
revenue growthP/E
MARKSANS PHARMAMARKSANS
Health Technology
54%similar
debt/equityoperating margin

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Mar '23

  1. AugPriceVolume reached 9.6x its 50-day median on 2026-08-11; price +5.2% that day.
  2. JunResultsYear-on-year EPS growth turned negative.
  3. JunPeer rankSlipped to the 3rd quartile of Health Technology on ROCE (from the 2nd quartile).
  4. MarPriceFell 62% from the Nov 2024 peak to the Mar 2026 low.
  5. MarPeer rankSlipped to the 2nd quartile of Health Technology on operating margin (from the top quartile).
  6. JanPriceVolume reached 21.3x its 50-day median on 2026-01-06; price +3.7% that day.
  7. NovPriceVolume reached 35.1x its 50-day median on 2025-11-11; price +10.8% that day.
  8. AugPriceVolume reached 6.1x its 50-day median on 2025-08-22; price +5.4% that day.
Show 22 earlier events
  1. JunPeer rankSlipped to the 2nd quartile of Health Technology on ROCE (from the top quartile).
  2. JunSharesShare count is up 6.2% over 12 months.
  3. MayPriceVolume reached 20.9x its 50-day median on 2025-05-06; price +7.3% that day.
  4. FebPriceVolume reached 8.5x its 50-day median on 2025-02-04; price +5.8% that day.
  5. DecPromoterPromoter holding fell 3.5 pts to 62.6%.
  6. DecInstitutionsFII + DII holding rose 5.0 pts over 1 quarter to 24.2%.
  7. NovPriceVolume reached 17.1x its 50-day median on 2024-11-25; price +16.3% that day.
  8. SepPromoterPromoter holding rose 12.9 pts to 66.0%.
  9. AugValuationP/E crossed above the 90th percentile of its own history to date (86.9x).
  10. JulPriceVolume reached 11.7x its 50-day median on 2024-07-08; price +2.0% that day.
  11. JunResultsRevenue (TTM) reached a new high of ₹1,376 cr.
  12. JunPeer rankMoved into the top quartile of Health Technology on ROCE (from the 2nd quartile).
  13. JunPriceVolume reached 52.2x its 50-day median on 2024-06-21; price +3.3% that day.
  14. FebPriceVolume reached 14.6x its 50-day median on 2024-02-21; price +1.4% that day.
  15. NovPriceVolume reached 11.8x its 50-day median on 2023-11-09; price +2.6% that day.
  16. AugValuationP/E crossed above the 90th percentile of its own history to date (78.4x).
  17. AugPriceVolume reached 22.9x its 50-day median on 2023-08-07; price +14.5% that day.
  18. JunResultsRevenue (TTM) reached a new high of ₹1,115 cr.
  19. JunPriceRegained the 2021-05 peak, 12 months after the low.
  20. JunPeer rankMoved into the top quartile of Health Technology on EPS growth (from the 2nd quartile).
  21. JunPriceVolume reached 98.5x its 50-day median on 2023-06-15; price +12.9% that day.
  22. MarPriceVolume reached 40.3x its 50-day median on 2023-03-01; price +7.0% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history60 months · 2021-12 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1151.9x₹1998 cr10.1%12.0%0.1x
2026-1046.6x₹1998 cr10.1%12.0%0.1x
2026-0953.8x₹1998 cr10.1%12.0%0.1x
2026-0855.4x₹1876 cr10.3%12.0%0.1x
2026-0753.5x₹1876 cr10.3%12.0%0.1x
2026-0653.1x₹1876 cr10.3%12.0%0.1x
2026-0539.3x₹1782 cr12.6%18.0%0.1x
2026-0444.1x₹1782 cr12.6%18.0%0.1x
2026-0334.7x₹1782 cr12.6%18.0%0.1x
2026-0235.2x₹1712 cr13.1%18.0%0.1x
2026-0142.6x₹1712 cr13.1%18.0%0.1x
2025-1249.7x₹1712 cr13.1%18.0%0.1x
2025-1154.9x₹1688 cr12.9%18.0%0.1x
2025-1056.7x₹1688 cr12.9%18.0%0.1x
2025-0955.2x₹1688 cr12.9%18.0%0.1x
2025-0861.7x₹1670 cr12.2%18.0%0.1x
2025-0757.3x₹1670 cr12.2%18.0%0.1x
2025-0665.8x₹1670 cr12.2%18.0%0.1x
2025-0570.9x₹1607 cr21.4%24.0%0.1x
2025-0480.8x₹1607 cr21.4%24.0%0.1x
2025-0370.5x₹1607 cr21.4%24.0%0.1x
2025-0267.3x₹1523 cr20.0%24.0%0.1x
2025-0177.1x₹1523 cr20.0%24.0%0.1x
2024-1286.5x₹1523 cr20.0%24.0%0.1x
2024-1199.1x₹1440 cr18.3%24.0%0.1x
2024-10102.3x₹1440 cr18.3%24.0%0.1x
2024-0982.4x₹1440 cr18.3%24.0%0.1x
2024-0886.9x₹1376 cr17.6%24.0%0.1x
2024-0769.5x₹1376 cr17.6%24.0%0.1x
2024-0671.7x₹1376 cr17.6%24.0%0.1x
2024-0596.4x₹1115 cr14.4%18.0%0.1x
2024-0487.9x₹1115 cr14.4%18.0%0.1x
2024-0385.0x₹1115 cr14.4%18.0%0.1x
2024-0283.6x₹1115 cr14.4%18.0%0.1x
2024-0177.9x₹1115 cr14.4%18.0%0.1x
2023-1279.7x₹1115 cr14.4%18.0%0.1x
2023-1181.6x₹1115 cr14.4%18.0%0.1x
2023-1075.2x₹1115 cr14.4%18.0%0.1x
2023-0973.5x₹1115 cr14.4%18.0%0.1x
2023-0878.4x₹1115 cr14.4%18.0%0.1x
2023-0766.1x₹1115 cr14.4%18.0%0.1x
2023-0661.5x₹1115 cr14.4%18.0%0.1x
2023-0563.8x₹922 cr13.5%17.0%0.1x
2023-0464.1x₹922 cr13.5%17.0%0.1x
2023-0362.3x₹922 cr13.5%17.0%0.1x
2023-0261.3x₹922 cr13.5%17.0%0.1x
2023-0158.6x₹922 cr13.5%17.0%0.1x
2022-1258.8x₹922 cr13.5%17.0%0.1x
2022-1164.0x₹922 cr13.5%17.0%0.1x
2022-1060.3x₹922 cr13.5%17.0%0.1x
2022-0956.6x₹922 cr13.5%17.0%0.1x
2022-0855.7x₹922 cr13.5%17.0%0.1x
2022-0747.8x₹922 cr13.5%17.0%0.1x
2022-0649.1x₹922 cr13.5%17.0%0.1x
2022-0552.9x₹785 cr14.1%22.0%0.1x
2022-0461.6x₹785 cr14.1%22.0%0.1x
2022-0367.0x₹785 cr14.1%22.0%0.1x
2022-0256.3x₹785 cr14.1%22.0%0.1x
2022-0163.6x₹785 cr14.1%22.0%0.1x
2021-1267.6x₹785 cr14.1%22.0%0.1x

Older months are in the live observatory.

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback